Fig. 5

ATP is growth suppressive in neurofibroma. (a) Daily administration of ATP (1 mg/g/day; I.P.) for 5d reduced cell proliferation. (b) ATP (50 mg/kg/day; I.P.) was administered from 1 to 6 mo. of age. Representative dissections of GEM-spinal cords with attached nerves and tumors in vehicle (PBS) and ATP-treated (ATP, right) littermate. Tumors are highlighted with red circles. (c) The diameter of tumors, measured at the widest portion parallel to the spinal cord, was reduced in the ATP treated versus vehicle (p = 0.0064). (d) Tumor number was also reduced (p = 0.0405). (e) Total percentage of EdU+ nuclei in PBS or ATP treated tumor bearing mice. (f) Proportion of EdU+ cells that co-labeled with the hematopoietic marker CD45. (g) Proportion of EdU+ cells that co-labeled with the SC marker Sox10. (h) Representative images from TUNEL assay, no difference observed. (i) Representative H&E staining of tumors from each cohort